United Therapeutics (UTHR) Tops Q4 EPS by 51c

United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $4.12, $0.51 better than the analyst estimate of $3.61. Revenue for the quarter came in at $409 million versus the consensus estimate of $415.51 million.

"Our annual 2016 financial results reflect continued growth as net revenues reached $1.6 billion and earnings exceeded $700 million," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "These financial results strengthen our ability to develop and advance our growing product pipeline, which includes seven phase III programs and multiple second generation Remodulin drug delivery systems

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance
• Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance